Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-12-27
2009-08-18
Anderson, Rebecca L (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
07576222
ABSTRACT:
This invention provides compounds of Formula I, having the structure:that are useful in treating diseases or disorders mediated by TNF-α. The invention further provides methods for use of the compounds for treating such a disease or disorder or for alleviating symptoms thereof.
REFERENCES:
patent: 5756546 (1998-05-01), Pirotte
patent: 5962529 (1999-10-01), Miller
patent: 6022898 (2000-02-01), Miller
patent: 6124332 (2000-09-01), Miller
patent: 6124333 (2000-09-01), Miller
patent: 6150394 (2000-11-01), Wantanabe
patent: 6197770 (2001-03-01), Natchus
patent: 6225311 (2001-05-01), Levin
patent: 6235768 (2001-05-01), Wantanabe
patent: 6277987 (2001-08-01), Kukkola
patent: 6326516 (2001-12-01), Levin
patent: 6340691 (2002-01-01), Levin
patent: 6358980 (2002-03-01), Levin
patent: 6423729 (2002-07-01), Kurihara et al.
patent: 6441021 (2002-08-01), Wantanabe
patent: 0757037 (1997-02-01), None
patent: 0877018 (1998-11-01), None
patent: 0877019 (1998-11-01), None
patent: 0878467 (1998-11-01), None
patent: 0967201 (1999-12-01), None
patent: 1233016 (2002-08-01), None
patent: 2508444 (1982-12-01), None
patent: 11246527 (1999-09-01), None
patent: 11343279 (1999-12-01), None
patent: WO 92/04320 (1992-03-01), None
patent: WO 97/27174 (1997-07-01), None
patent: WO 99/04780 (1999-02-01), None
patent: WO 99/51572 (1999-10-01), None
patent: WO 00/15213 (2000-03-01), None
patent: WO 00/27808 (2000-05-01), None
patent: WO 00/58280 (2000-05-01), None
patent: WO 00/44709 (2000-08-01), None
patent: WO 00/44723 (2000-08-01), None
patent: WO 00/51975 (2000-09-01), None
patent: WO 00/58304 (2000-10-01), None
patent: WO 01/10827 (2001-02-01), None
patent: WO 01/27084 (2001-04-01), None
patent: WO 01/55133 (2001-08-01), None
patent: WO 01/70682 (2001-09-01), None
patent: WO 01/70690 (2001-09-01), None
patent: WO 01/70691 (2001-09-01), None
patent: WO 01/70693 (2001-09-01), None
patent: WO 01/70720 (2001-09-01), None
patent: WP 01/83463 (2001-11-01), None
patent: WO 02/067866 (2002-09-01), None
patent: WO 02/088115 (2002-11-01), None
patent: WO 03/035610 (2003-05-01), None
patent: WO 03/091250 (2003-11-01), None
Metastasis [onlone] {retrieved on Apr. 12, 2008 from the Internet} {URL: http://www.healthline.com/adamcontent/metastasis?utm+medium=ask&utm—source=smart.
Diabetes Mellitus [online], [retrieved on Apr. 17, 2007]. Retrieved from the Internet, URL: http:||www.merck.com|mmpe|print|sec|2/ch 158/ch 158b.html>.
Cancer and Metastasis Reviews (1998), 17(1 ), 91-106.
Science (1999), vol. 286, 531-537.
Cancer [online], [retrieved on Jul. 6, 2007]. Retrieved from the Internet, URL: http:||www.nlm.nih.gov|medlineplus|cancer.html>.
Cancer [online], [retrieved on Jul. 6, 2007]. Retrieved from the Internet, URL: http:||en.wikipedia.org|wiki|Cancer>.
Beutler et al., “Tumour necrosis, cachexia, shock, and inflammation: a common mediator,”Ann Rev Biochem(1988) 57:505-518.
Camussi et al., “The Future Role of Anti-Tumour Necrosis Factor (TNF) Products in the Treatment of Rheumatoid Arthritis,”Drugs(1998) 55(5):613-620.
Ferrari et al., “Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure,”Circulation(1995) 92(6):1479.
Gilchrist et al., “Addition and cycloaddition reactions of the electrophilic vinyl nitroso compounds 3-nitrosobut-3-en-2-one, 2-nitrosopropenal, and ethyl 2-nitrosopropenoate,”J Chem Soc Perkin, Trans 1(1983) 1283-1292.
Grossman et al., “Rheumatoid arthritis: current clinical and research directions,”J. Women's Health(1997) 6(6):627.
Hotamisligil et al., “Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance,”Science(1993) 259:87.
Isomaki et al., “Pro- and anti-inflammatory cytokines in rheumatoid arthritis,”Ann Med(1997) 29:499.
Jin et al., “Crystal structure of the catalytic domain of a human thioredoxin-like protein,”Analytical Biochemistry(2002) 302:269-275.
Knight et al., “A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases,”FEBS Lett(1992) 296:263-266.
Ksontini et al., “Revisiting the role of tumor necrosis factor alpha and the response to surgical injury and inflammation,”Arch Surg(1998) 133:558.
Li et al., “The genetic study of retinoblastoma,”Synthesis(1988) 73-76.
Mathison et al., “Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits,”J Clin Invest(1988) 81:1925.
McGeehan et al., “TNF-alpha in human diseases,”Current Pharmaceutical Design(1996) 2(6):662-667.
Miethke et al., “T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor,”J Exp Med(1992) 175:91.
Newton et al., “Biology of TACE inhibition,”Ann Rheum Dis(2001) 60:iii25-iii32.
Old “Tumor necrosis factor (TNF),”Science(1985) 230:630.
Pallares-Trujillo et al., “TNF and AIDS: two sides of the same coin?,”Med Res Reviews(1995) 15(6):533-546.
Packer “Is tumor necrosis factor an important neurohormonal mechanism in chronic heart failure?,”Circulation(1995) 92(6):1379.
Peterson et al., “Human cytomegalovirus-stimulated peripheral blood mononuclear cells induce HIV-1 replication via a tumor necrosis factor-alpha-mediated mechanism,”J Clin Invest(1992) 89:574.
Piguet et al., “Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease,”J Exp Med(1987) 166:1280.
Rankin et al., “The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis,”Br J Rheumatol(1995) 34:334.
Shire et al., “TNF-α inhibitors and rheumatoid arthritis,”Exp Opin Ther. Patents(1998) 8(5):531-544.
Zhang et al., “Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis,”Journal of Pharmacology and Experimental Therapeutics(2004) 309:348-355.
Pharmaprojects(1996), Therapeutic Updates 17(Oct.), au197-au198.
Scrip(1998) 2349:2.
Brynskov, J. et al., “Tumor necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease”, Gut, 2002, 51: 37-43.
Rutgeerts, P. and Baert, F., “Novel therapies for Crohn's disease”, Drugs of Today, 2000, 36 (Suppl. G), 59-68.
Lovell, D.J. et al., “Long-Term Efficacy and Safety of Etanercept in Children With Polyarticular-Course Juvenile Rheumatoid Arthritis”, Arthritis & Rheumatism, 2003, 48(1): 218-226.
Calamia, K.T., “Current and future use of anti-TNF agents in the treatment of autoimmune, inflammatory disorders”, Advances in Experimental Medicine and Biology, 2003, 528 (Adamantiades-Behcet's Disease), 545-549.
Gopalsamy Ariamala
Levin Jeremy I.
Park Kaapjoo
Anderson Rebecca L
Pepper Hamilton LLP
Wyeth
Young Shawquia
LandOfFree
Alkynyl-containing tryptophan derivative inhibitors of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alkynyl-containing tryptophan derivative inhibitors of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alkynyl-containing tryptophan derivative inhibitors of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4111478